This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Efficacy Profile | Reducing Risk of DVT/PE Recurrence | Pradaxa® (dabigatran etexilate) Skip to main content
  • References:
  • 1. Data on File. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 3. Schulman S, Kearon C, Kakkar AK; for the RE‑MEDY and the RE‑SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709‑718.